99mTc- and111In-labeled α-melanocyte- stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection

Yubin Miao; Katherine Benwell; Thomas P. Quinn

^99mTc- and¹¹¹In-labeled α-melanocyte- stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection

Yubin Miao
, Katherine Benwell
, Thomas P. Quinn

University of Missouri
VA Medical Center

Research output: Contribution to journal › Article › peer-review

96 Scopus citations

Abstract

It is highly desired to develop new imaging probes for early detection of melanoma as early diagnosis and prompt surgical removal are a patient's best hope for a cure. The purpose of this study was to determine whether ^99mTc- and ¹¹¹In-labeled α-melanocyte-stimulating hormone (α-MSH) peptides could be used as imaging probes for primary and metastatic melanoma using dual-modality micro-SPECT/CT detection. Methods: [Cys^3,4,10,D-Phe⁷,Arg¹¹]α-MSH _3-13 [(Arg¹¹)CCMSH] and [1,4,7, 10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid]Re(Arg¹¹)-CCMSH [DOTA-Re(Arg ¹¹)CCMSH] were labeled with ^99mTc and ¹¹¹In. The pharmacokinetics of ^99mTc-(Arg¹¹)CCMSH were examined in B16/F1 flank and B16/F10 pulmonary metastatic murine melanoma-bearing C57 mice. The biodistribution of ¹¹¹In-DOTA-Re(Arg¹¹)CCMSH was performed in B16/F10 pulmonary metastatic murine melanoma-bearing C57 mice. SPECT/CT of ^99mTc-(Arg¹¹)CCMSH and ¹¹¹In-DOTA- Re(Arg¹¹)-CCMSH was determined in B16/F1 flank and B16/F10 pulmonary metastatic murine melanoma-bearing C57 mice. Results: ^99mTc-(Arg ¹¹)CCMSH and ¹¹¹In-DOTA-Re(Arg¹¹)CCMSH exhibited high tumor uptakes (14.03 ± 2.58 percentage injected dose/gram [%ID/g] at 1 h after injection and 17.29 ± 2.49 %ID/g at 2 h after injection) in B16/F1 melanoma-bearing mice, and the flank melanoma tumors were clearly imaged by micro-SPECT/CT. Nontarget organ uptakes were considerably lower except for the kidneys. B16/F10 pulmonary melanoma metastases were also clearly visualized by micro-SPECT/CT using ^99mTc-(Arg ¹¹)CCMSH or ¹¹¹In-DOTA-Re(Arg¹¹)CCMSH as the imaging probe. ^99mTc-(Arg¹¹)CCMSH exhibited images with greater resolution of metastatic melanoma lesions compared with ¹¹¹In-DOTA-Re(Arg¹¹)CCMSH. Conclusion: The favorable tumor imaging properties of 99mTc-(Arg¹¹)CCMSH and ¹¹¹In-DOTA- Re(Arg¹¹)CCMSH highlighted their potential as novel probes for primary and metastatic melanoma detection.

Original language	English
Pages (from-to)	73-80
Number of pages	8
Journal	Journal of Nuclear Medicine
Volume	48
Issue number	1
State	Published - Jan 1 2007

Keywords

α-melanocyte-stimulating hormone
Tc- and In-labeled peptides
Primary and metastatic melanoma detection

Cite this

@article{7bd7e160d9fd4797aba007f8d33d221d,

title = "99mTc- and111In-labeled α-melanocyte- stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection",

abstract = "It is highly desired to develop new imaging probes for early detection of melanoma as early diagnosis and prompt surgical removal are a patient's best hope for a cure. The purpose of this study was to determine whether 99mTc- and 111In-labeled α-melanocyte-stimulating hormone (α-MSH) peptides could be used as imaging probes for primary and metastatic melanoma using dual-modality micro-SPECT/CT detection. Methods: [Cys3,4,10,D-Phe7,Arg11]α-MSH 3-13 [(Arg11)CCMSH] and [1,4,7, 10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid]Re(Arg11)-CCMSH [DOTA-Re(Arg 11)CCMSH] were labeled with 99mTc and 111In. The pharmacokinetics of 99mTc-(Arg11)CCMSH were examined in B16/F1 flank and B16/F10 pulmonary metastatic murine melanoma-bearing C57 mice. The biodistribution of 111In-DOTA-Re(Arg11)CCMSH was performed in B16/F10 pulmonary metastatic murine melanoma-bearing C57 mice. SPECT/CT of 99mTc-(Arg11)CCMSH and 111In-DOTA- Re(Arg11)-CCMSH was determined in B16/F1 flank and B16/F10 pulmonary metastatic murine melanoma-bearing C57 mice. Results: 99mTc-(Arg 11)CCMSH and 111In-DOTA-Re(Arg11)CCMSH exhibited high tumor uptakes (14.03 ± 2.58 percentage injected dose/gram [\%ID/g] at 1 h after injection and 17.29 ± 2.49 \%ID/g at 2 h after injection) in B16/F1 melanoma-bearing mice, and the flank melanoma tumors were clearly imaged by micro-SPECT/CT. Nontarget organ uptakes were considerably lower except for the kidneys. B16/F10 pulmonary melanoma metastases were also clearly visualized by micro-SPECT/CT using 99mTc-(Arg 11)CCMSH or 111In-DOTA-Re(Arg11)CCMSH as the imaging probe. 99mTc-(Arg11)CCMSH exhibited images with greater resolution of metastatic melanoma lesions compared with 111In-DOTA-Re(Arg11)CCMSH. Conclusion: The favorable tumor imaging properties of 99mTc-(Arg11)CCMSH and 111In-DOTA- Re(Arg11)CCMSH highlighted their potential as novel probes for primary and metastatic melanoma detection.",

keywords = "α-melanocyte-stimulating hormone, Tc- and In-labeled peptides, Primary and metastatic melanoma detection",

author = "Yubin Miao and Katherine Benwell and Quinn, \{Thomas P.\}",

year = "2007",

month = jan,

day = "1",

language = "English",

volume = "48",

pages = "73--80",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

number = "1",

}

TY - JOUR

T1 - 99mTc- and111In-labeled α-melanocyte- stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection

AU - Miao, Yubin

AU - Benwell, Katherine

AU - Quinn, Thomas P.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - It is highly desired to develop new imaging probes for early detection of melanoma as early diagnosis and prompt surgical removal are a patient's best hope for a cure. The purpose of this study was to determine whether 99mTc- and 111In-labeled α-melanocyte-stimulating hormone (α-MSH) peptides could be used as imaging probes for primary and metastatic melanoma using dual-modality micro-SPECT/CT detection. Methods: [Cys3,4,10,D-Phe7,Arg11]α-MSH 3-13 [(Arg11)CCMSH] and [1,4,7, 10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid]Re(Arg11)-CCMSH [DOTA-Re(Arg 11)CCMSH] were labeled with 99mTc and 111In. The pharmacokinetics of 99mTc-(Arg11)CCMSH were examined in B16/F1 flank and B16/F10 pulmonary metastatic murine melanoma-bearing C57 mice. The biodistribution of 111In-DOTA-Re(Arg11)CCMSH was performed in B16/F10 pulmonary metastatic murine melanoma-bearing C57 mice. SPECT/CT of 99mTc-(Arg11)CCMSH and 111In-DOTA- Re(Arg11)-CCMSH was determined in B16/F1 flank and B16/F10 pulmonary metastatic murine melanoma-bearing C57 mice. Results: 99mTc-(Arg 11)CCMSH and 111In-DOTA-Re(Arg11)CCMSH exhibited high tumor uptakes (14.03 ± 2.58 percentage injected dose/gram [%ID/g] at 1 h after injection and 17.29 ± 2.49 %ID/g at 2 h after injection) in B16/F1 melanoma-bearing mice, and the flank melanoma tumors were clearly imaged by micro-SPECT/CT. Nontarget organ uptakes were considerably lower except for the kidneys. B16/F10 pulmonary melanoma metastases were also clearly visualized by micro-SPECT/CT using 99mTc-(Arg 11)CCMSH or 111In-DOTA-Re(Arg11)CCMSH as the imaging probe. 99mTc-(Arg11)CCMSH exhibited images with greater resolution of metastatic melanoma lesions compared with 111In-DOTA-Re(Arg11)CCMSH. Conclusion: The favorable tumor imaging properties of 99mTc-(Arg11)CCMSH and 111In-DOTA- Re(Arg11)CCMSH highlighted their potential as novel probes for primary and metastatic melanoma detection.

AB - It is highly desired to develop new imaging probes for early detection of melanoma as early diagnosis and prompt surgical removal are a patient's best hope for a cure. The purpose of this study was to determine whether 99mTc- and 111In-labeled α-melanocyte-stimulating hormone (α-MSH) peptides could be used as imaging probes for primary and metastatic melanoma using dual-modality micro-SPECT/CT detection. Methods: [Cys3,4,10,D-Phe7,Arg11]α-MSH 3-13 [(Arg11)CCMSH] and [1,4,7, 10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid]Re(Arg11)-CCMSH [DOTA-Re(Arg 11)CCMSH] were labeled with 99mTc and 111In. The pharmacokinetics of 99mTc-(Arg11)CCMSH were examined in B16/F1 flank and B16/F10 pulmonary metastatic murine melanoma-bearing C57 mice. The biodistribution of 111In-DOTA-Re(Arg11)CCMSH was performed in B16/F10 pulmonary metastatic murine melanoma-bearing C57 mice. SPECT/CT of 99mTc-(Arg11)CCMSH and 111In-DOTA- Re(Arg11)-CCMSH was determined in B16/F1 flank and B16/F10 pulmonary metastatic murine melanoma-bearing C57 mice. Results: 99mTc-(Arg 11)CCMSH and 111In-DOTA-Re(Arg11)CCMSH exhibited high tumor uptakes (14.03 ± 2.58 percentage injected dose/gram [%ID/g] at 1 h after injection and 17.29 ± 2.49 %ID/g at 2 h after injection) in B16/F1 melanoma-bearing mice, and the flank melanoma tumors were clearly imaged by micro-SPECT/CT. Nontarget organ uptakes were considerably lower except for the kidneys. B16/F10 pulmonary melanoma metastases were also clearly visualized by micro-SPECT/CT using 99mTc-(Arg 11)CCMSH or 111In-DOTA-Re(Arg11)CCMSH as the imaging probe. 99mTc-(Arg11)CCMSH exhibited images with greater resolution of metastatic melanoma lesions compared with 111In-DOTA-Re(Arg11)CCMSH. Conclusion: The favorable tumor imaging properties of 99mTc-(Arg11)CCMSH and 111In-DOTA- Re(Arg11)CCMSH highlighted their potential as novel probes for primary and metastatic melanoma detection.

KW - α-melanocyte-stimulating hormone

KW - Tc- and In-labeled peptides

KW - Primary and metastatic melanoma detection

UR - https://www.scopus.com/pages/publications/33847279936

M3 - Article

C2 - 17204701

AN - SCOPUS:33847279936

SN - 0161-5505

VL - 48

SP - 73

EP - 80

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 1

ER -

^99mTc- and¹¹¹In-labeled α-melanocyte- stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection

Abstract

Keywords

Other files and links

Fingerprint

Cite this